ADME-Toxicology Testing Market Trends, Analysis, Share and Future Demand 2023

Posted by Aryan on July 10th, 2018

ADME-toxicology testing has witnessed significant growth in the drug development in recent years. Most often the development of new drug is a very critical for the drug developers, attributed mainly to the high cost proposal for pharmaceutical and large attrition rate at various stages of drug development. The conventional drug development uses vivo model of toxicity testing.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/adme-toxicology-testing-market/report-sample

Based on the different product type, global ADME-toxicology testing market can be bifurcated as instruments, software solutions, assays systems, reagents and others. Based on the technology used in the ADME-toxicology testing the market can be bifurcated as in-vivo (implemented inside a living organism), and in-vitro (test performed in a laboratory). Further In-vitro technology is bifurcated as biochemical testing and cell testing (including liver, intestinal, kidney). In-vitro technology is expected to witness the highest growth during the forecast period attributed mainly to the growing concern over animal rights for using animals for clinical trials. In-vivo is still the largest used toxicity testing technology owing to its cost and time benefits over other toxicity testing technique. With benefits such as increase throughput screening, the ADME toxicology prediction technology is expected to increase in coming years.

Asia Pacific is expected to be the fasted growing market of ADME-Toxicology Testing during the forecast period. The growth is mainly anticipated from the supporting government initiatives and increasing number of merger and accusation (M&A) in pharmaceutical companies and research laboratories.

Browse Full Report at: https://www.psmarketresearch.com/market-analysis/adme-toxicology-testing-market

Some of the major players operating in the Global ADME-Toxicology Testing Market include, Accelrys, Inc., Agilent Technologies, Inc., Caliper Life Sciences, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Cellartis AB, Cyprotex PLC., Life Technologies Corporation, Optivia Biotechnology, Inc., Thermo Fisher Scientific, Inc., Molecular Discovery Ltd., Cyprotex PLC, MultiCASE, Inc., Promega Corporation, Xceleron, Inc., ACEA Biosciences, Inc., Albany Molecular Research, Inc., Beckman Coulter, Inc., CeeTox, Inc., Molecular Discovery Ltd.